Recombinant Human GMPPB Protein: Function & Research Use

Recombinant Human GMPPB Protein is a key enzyme reagent supporting research into GDP-mannose biosynthesis, protein glycosylation pathways, and the molecular mechanisms underlying GMPPB-associated congenital muscular dystrophies and limb-girdle muscular dystrophies.

Protein Name

Recombinant Human GMPPB Protein

Gene Name

GMPPB (GDP-mannose pyrophosphorylase B)

Primary Function

Catalyzes the synthesis of GDP-mannose from GTP and mannose-1-phosphate

Disease Relevance

Mutations linked to congenital muscular dystrophy and limb-girdle muscular dystrophy with intellectual disability

Research Applications

Glycosylation studies, enzyme activity assays, protein interaction studies, disease modeling

Product SKU

rp371439

What Is GMPPB and Why Does It Matter?

GMPPB (GDP-mannose pyrophosphorylase B) is a nucleotide sugar biosynthesis enzyme responsible for catalyzing the conversion of GTP and mannose-1-phosphate into GDP-mannose. GDP-mannose is an essential sugar-nucleotide donor required for the proper glycosylation of multiple proteins, most critically alpha-dystroglycan (α-DG), a key component of the dystrophin-associated glycoprotein complex that links the intracellular cytoskeleton to the extracellular matrix in muscle cells.

Adequate levels of functional GMPPB are therefore indispensable for maintaining the structural integrity and signaling competence of muscle fibers. Disruption of GMPPB activity leads to hypoglycosylation of α-DG, compromising its ability to bind laminin and other extracellular matrix proteins, ultimately resulting in muscular dystrophy phenotypes. The GMPPB gene is located on chromosome 3p21 in humans, and its protein product functions as part of the broader family of dystroglycanopathies.

GMPPB Mutations and Associated Disease Phenotypes

Loss-of-function or hypomorphic mutations in GMPPB have been identified as causative for a spectrum of muscular dystrophies classified within the dystroglycanopathies. These include congenital muscular dystrophy (CMD) with structural brain involvement and limb-girdle muscular dystrophy type 2T (LGMD2T), now reclassified as LGMD-R20. Clinical presentations range from severe congenital onset with intellectual disability and epilepsy to milder adult-onset proximal muscle weakness.

The genotype-phenotype correlation in GMPPB-related disease is complex: residual enzyme activity correlates broadly with disease severity, with near-complete loss of function associated with the most severe CMD phenotypes. Functional characterization of mutant GMPPB proteins using recombinant reagents has been instrumental in understanding how specific amino acid substitutions alter enzyme kinetics, thermostability, and GDP-mannose output. These insights directly inform potential therapeutic strategies, including enzyme replacement and pharmacological chaperone approaches.

Research Applications of Recombinant Human GMPPB Protein

Recombinant Human GMPPB Protein serves as a versatile reagent across multiple experimental contexts:

• Enzyme activity assays: The recombinant protein enables direct measurement of GDP-mannose pyrophosphorylase activity using spectrophotometric or coupled-enzyme assays, providing quantitative kinetic parameters (Km, Vmax, kcat) under controlled conditions.
• Mutant protein characterization: Researchers use the wild-type recombinant protein as a reference standard when comparing enzymatic properties of disease-associated GMPPB variants produced recombinantly or isolated from patient-derived samples.
• Protein–protein interaction studies: Pull-down assays and co-immunoprecipitation experiments using recombinant GMPPB can identify novel binding partners within the nucleotide sugar biosynthesis pathway and the broader glycosylation machinery.
• Structural biology: Purified recombinant GMPPB protein supports crystallography and cryo-EM studies aimed at resolving the enzyme's three-dimensional structure, which is important for structure-based drug design targeting dystroglycanopathies.
• Antibody validation: Recombinant protein serves as a positive control antigen for validating GMPPB-specific antibodies in Western blot, ELISA, and immunofluorescence applications.

Handling, Storage, and Quality Considerations

To ensure optimal performance of Recombinant Human GMPPB Protein in downstream assays, researchers should adhere to the following general best practices (always consult the specific product datasheet for confirmed specifications):

• Storage: Recombinant proteins are generally stored at –80 °C for long-term stability. Avoid repeated freeze-thaw cycles, which can reduce enzymatic activity and promote aggregation. Aliquot upon first thaw.
• Buffer compatibility: Confirm that the supplied formulation buffer is compatible with your assay system. Common formulations include phosphate-buffered saline (PBS) with stabilizing additives such as glycerol or BSA. Dialysis or buffer exchange may be required for specific assay formats.
• Purity and endotoxin: For cell-based and in vivo studies, verify endotoxin levels meet experimental requirements. Purity should be assessed by SDS-PAGE and, where relevant, by functional activity assay.
• Quality controls: Each lot of Aladdin Scientific recombinant protein undergoes identity verification and purity assessment to support reproducible experimental outcomes.

Frequently asked questions

What is the biological function of GMPPB?

GMPPB (GDP-mannose pyrophosphorylase B) catalyzes the synthesis of GDP-mannose from GTP and mannose-1-phosphate. GDP-mannose is a critical nucleotide sugar donor required for the glycosylation of proteins including alpha-dystroglycan, which is essential for normal muscle and neurological function.

What diseases are associated with GMPPB mutations?

Mutations in GMPPB cause a spectrum of dystroglycanopathies, including congenital muscular dystrophy (CMD) with brain involvement and limb-girdle muscular dystrophy type LGMD-R20 (formerly LGMD2T). Severity varies from severe congenital presentations with intellectual disability to milder adult-onset muscle weakness, broadly correlating with residual enzyme activity.

How should Recombinant Human GMPPB Protein be stored to maintain activity?

Recombinant Human GMPPB Protein should generally be stored at –80 °C for long-term preservation. Repeated freeze-thaw cycles should be avoided to prevent loss of enzymatic activity and protein aggregation; it is recommended to aliquot the protein upon first thaw. Always refer to the product-specific datasheet for confirmed storage conditions.

What experimental applications is Recombinant Human GMPPB Protein suitable for?

Recombinant Human GMPPB Protein is suitable for a range of applications including enzyme kinetics and activity assays, characterization of disease-associated mutant variants, protein-protein interaction studies (pull-down, co-IP), structural biology (crystallography, cryo-EM), and as a positive control antigen for antibody validation in Western blot and ELISA formats.

Is Recombinant Human GMPPB Protein suitable for cell-based assays?

Recombinant Human GMPPB Protein may be used in cell-based research contexts, but it is essential to confirm that endotoxin levels in the specific lot meet the requirements of your assay. Researchers should consult the product datasheet and, if necessary, perform endotoxin testing before use in sensitive cellular systems.

References

1. Carss KJ, et al. Mutations in GDP-mannose pyrophosphorylase B cause congenital and limb-girdle muscular dystrophies associated with hypoglycosylation of alpha-dystroglycan. American Journal of Human Genetics. 2013.
2. Raphael AR, et al. Mutations in GMPPB cause dystroglycanopathy. Neurology. 2014.
3. Freeze HH, et al. Solving glycosylation disorders: fundamental approaches reveal complicated pathways. American Journal of Human Genetics. 2014.

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.